AOD-9604: The Fat Loss Peptide You’ll Soon Be Able to Get Again
By Dr. Jossy Onwude, MD
AOD-9604 is one of the few “fat-loss peptides” that was originally developed in a conventional drug-development pipeline—long before peptides became a wellness trend. It’s also one of the most misunderstood.
If you’ve been searching for AOD-9604 lately, you’re probably trying to answer some practical questions:
- Does it actually work for fat loss—or is it hype?
- How does it compare to semaglutide or tirzepatide?
- Is it safe?
- Why did it “disappear,” and is it really coming back?
This article is written for Meto’s weight-loss audience: people who want clinically grounded guidance, not marketing.
I’ll cover how AOD-9604 works (and what it doesn’t do), what the human research suggests, why results have been mixed, how it compares to GLP-1/GIP medications, and what “legal again” actually means in the U.S. compounding landscape.
Important note: This is educational, not medical advice. Peptide quality, dosing, route of administration, and patient selection matter enormously—and the U.S. regulatory picture is still evolving.
Related Meto reading (recommended context):
- “14 Peptides Are About to Become Legal Again — What This Means for Your Health”
- “Peptides vs GLP-1s: Competitors or Companions in Metabolic Health?”
What is AOD-9604?
AOD-9604 is a modified fragment of human growth hormone (hGH), derived from the C-terminal region commonly described as hGH 176–191 (sometimes written as Tyr-hGH 177–191). It was designed to preserve growth hormone’s fat-metabolism effects while avoiding many of the growth-promoting and glucose-worsening issues associated with full-length hGH. (jofem.org)
That distinction matters because AOD-9604 is often marketed as “HGH for fat loss,” which is not accurate in any clinically meaningful way.
What AOD-9604 is not
- Not full growth hormone.
- Not a GLP-1 medication.
- Not primarily an appetite suppressant.
- Not FDA-approved for weight loss.
How AOD-9604 works (mechanism, in plain clinical terms)
The simplest way to understand AOD-9604 is this:
GLP-1s help many patients eat less and improve glycemic control.
AOD-9604 is aimed at fat-cell signaling—helping fat tissue break down stored triglyceride and resist new fat storage.
Mechanistic themes seen in preclinical research
In animal and mechanistic work, AOD-9604 has been associated with:
- Increased lipolysis (breaking down stored fat)
- Reduced lipogenesis (reducing fat storage)
- Interactions with β-adrenergic pathways in adipose tissue have been discussed as part of its lipolytic signaling profile (OUP Academic)
In obese animal models, AOD-9604 has shown reductions in body weight and body fat and changes consistent with increased fat mobilization. (OUP Academic)
What it doesn’t do (important for expectations)
AOD-9604 is not designed to:
- strongly suppress appetite,
- slow gastric emptying,
- meaningfully lower A1c by itself.
So if your main barrier is appetite dysregulation, food noise, or post-meal cravings, AOD-9604 is not a like-for-like substitute for semaglutide or tirzepatide.
What the human evidence actually shows
AOD-9604 has a surprisingly large “paper trail” for a peptide—because it went through multiple controlled trials.
A safety review in the Journal of Obesity & Food Metabolism describes six randomized, double-blind, placebo-controlled trials evaluating AOD-9604, including oral dosing studies and longer phase II programs. (jofem.org)
The best-case signal: modest weight loss in a shorter trial
A frequently cited 12-week randomized trial result (as summarized in reviews) reported:
- ~2.6 kg average loss with AOD-9604 1 mg/day
- vs ~0.8 kg with placebo (PMC)
This is the kind of result that can be statistically meaningful, clinically modest, and very sensitive to study design (diet, activity, baseline metabolic status, adherence).
The reality check: longer trials did not justify a commercial obesity drug
The same obesity-pharmacotherapy review literature notes that development was terminated after a longer trial failed to demonstrate sufficiently meaningful weight loss to be commercially viable. (PMC)
A separate metabolism-focused paper reviewing human trial history makes a similar point: early signals of weight loss were not consistently reproduced in later studies, particularly when intensive diet/exercise protocols were included. (jofem.org)
Clinical interpretation (without hype)
Here’s the honest, clinically grounded framing:
- AOD-9604 is not “fake.” There is real preclinical plausibility and real human trial activity. (jofem.org)
- But it is also not a modern obesity medication. It did not produce the magnitude of weight loss we now consider “transformative,” which is why it never became a mainstream drug.
If you compare it to what we see with GLP-1/GIP therapy, the gap is obvious (more on that below).
Safety: what we know, what we don’t
What clinical trial safety reviews suggest
The clinical safety review literature reports several reassuring signals:
- No meaningful increase in IGF-1 in monitored long-term studies (jofem.org)
- No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org)
- No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org)
The major limitation: long-term real-world certainty is thin
The problem with many peptides is not that “everything is dangerous”—it’s that the certainty level is often lower than patients assume.
Even if clinical trials suggest tolerability, the real-world risk profile changes when:
- the source and purity of the peptide are uncertain,
- it’s used in different routes than studied,
- it’s used in stacked protocols with other drugs,
- it’s used in populations the trials didn’t represent.
A doping/sport note (because it comes up in searches)
WADA’s prohibited list explicitly references growth hormone fragments, including AOD-9604 / hGH 176–191. (wada-ama.org)
If you’re tested in sport, this matters regardless of your intent.
AOD-9604 vs semaglutide vs tirzepatide
People often compare these because they’re all discussed in “weight loss” conversations. Mechanistically and clinically, they’re not close cousins.
Mechanism difference
- Semaglutide (GLP-1 agonist): appetite regulation, satiety, improved glycemic control (New England Journal of Medicine)
- Tirzepatide (GLP-1/GIP agonist): broader incretin effects, robust appetite/weight effects (New England Journal of Medicine)
- AOD-9604: targeted fat-metabolism signaling; not primarily appetite-driven (OUP Academic)
Expected weight loss (this is where many people get misled)
In major obesity trials:
- Semaglutide 2.4 mg weekly: ~14.9% mean weight loss at 68 weeks (STEP-1) (PubMed)
- Tirzepatide: ~15.0% to ~20.9% mean weight loss at 72 weeks, dose-dependent (SURMOUNT-1) (PubMed)
AOD-9604’s best-known human signal is kilograms, not double-digit percentages, and later studies did not sustain a strong obesity-drug profile. (PMC)
Related Read: Oral Tirzepatide Drops: What They Are, How They Work, and What to Know
The practical “who is it for?” view
- If you need meaningful, sustained appetite control and metabolic correction, GLP-1/GIP therapy is usually the cornerstone.
- If appetite is already well controlled (by lifestyle, GLP-1s, or both) and you’re exploring body composition refinement, AOD-9604 is sometimes discussed as an adjunct—but expectations must stay realistic.
For Meto’s audience, the key is this: AOD-9604 is not a replacement for GLP-1s. If it has a role, it’s more like a “supporting actor” than a lead therapy.
Can AOD-9604 be combined with GLP-1 medications?
This is a common question, and it’s where responsible clinics differ from peptide hype shops.
The theoretical rationale (why clinics consider it)
- GLP-1/GIP therapy reduces intake and improves metabolic parameters.
- AOD-9604 is proposed to support fat mobilization / reduce fat storage signaling.
In theory, that’s complementary: appetite and intake on one side, fat tissue signaling on the other.
The evidence reality
There is no robust, high-quality human outcomes literature showing that adding AOD-9604 to semaglutide or tirzepatide produces clinically meaningful additional fat loss beyond what GLP-1/GIP therapy already achieves.
So if a clinic frames the combo as “guaranteed faster fat loss,” that’s marketing, not evidence.
A more clinically honest way to think about combination therapy
If you’re already on GLP-1/GIP therapy and plateaued, the first questions are usually:
- Are you undereating protein and losing lean mass?
- Is your activity/NEAT drifting down due to lower appetite?
- Is your sleep poor, stress high, or alcohol intake creeping up?
- Are you dealing with constipation/gastric slowdown, reducing adherence?
Only after those are addressed does it make sense to discuss adjuncts—peptides included.
This is the broader theme in Meto’s companion piece: peptides and GLP-1s are not inherently competitors; but “companion” only makes sense when the physiology and the plan make sense. (Peptides vs GLP-1s.)
Why people are saying AOD-9604 is “coming back”
This is where the conversation often gets sloppy online.
What FDA has said recently (high-level, patient-friendly summary)
FDA maintains a page describing certain bulk drug substances used in compounding that may present significant safety risks, including AOD-9604, noting concerns such as potential immunogenicity and limited safety-related information for some uses/routes. (U.S. Food and Drug Administration)
Separately, FDA documentation around the 503A bulks process shows AOD-9604’s status has moved around as nominations were withdrawn and advisory committee discussions occurred. For example:
- FDA communications indicate AOD-9604 was removed from “Category 2” in 2024 because nominations were withdrawn, while also noting FDA would consult the Pharmacy Compounding Advisory Committee (PCAC) about potential inclusion on the 503A bulks list. (U.S. Food and Drug Administration)
- FDA meeting materials indicate FDA proposed that certain AOD-9604 forms not be included on the 503A bulks list at that time. (U.S. Food and Drug Administration)
Peptide therapy, done properly.
Personalized treatment recommendations based on your labs—not trends. Work with experienced clinicians to develop a peptide protocol that fits your biology.
What “legal again” would actually require
For a peptide to be straightforwardly compoundable under typical 503A pathways, it generally needs a clear permissible status under the applicable rules/guidance—this isn’t just a social media announcement.
So the most accurate way to say it is: Interest is rising because regulatory status is being actively discussed and revisited—but “available again” depends on the exact FDA position and the compounding pathway.
If you want the broader landscape (and the list of other peptides driving search interest), see Meto’s internal piece: “14 Peptides Are About to Become Legal Again — What This Means for Your Health.”
Who should consider AOD-9604 (and who shouldn’t)
Consider it only if your expectations are realistic
AOD-9604 may be worth a conversation if you are:
- Already doing the fundamentals (protein, resistance training, sleep)
- Not seeking massive scale weight loss
- Looking at fat-loss support rather than appetite suppression
- Intolerant of GLP-1s and exploring alternatives (with the understanding that alternatives are usually less powerful)
Avoid it if…
- You have significant obesity and need a high-efficacy therapy (GLP-1/GIP class is typically far more impactful) (PubMed)
- You’re hoping it will “melt fat” without dietary alignment
- Your plan depends on unverified sources or “research peptide” suppliers
- You’re in a drug-tested sport environment (WADA prohibition is relevant) (wada-ama.org)
Practical expectations (what most people want to know)
How fast does it work?
If it works for you, the expected effect is more along the lines of:
- modest shifts in fat loss over weeks to months,
- not dramatic weekly scale drops.
Will it curb hunger?
No—at least not in the way semaglutide/tirzepatide do. If hunger is the main driver of weight regain, GLP-1/GIP strategies tend to be more directly matched to the problem. (PubMed)
Is it better for “stubborn fat”?
There’s no strong human evidence to support spot-reduction claims. “Stubborn fat” is usually about:
- genetics and fat distribution,
- hormones and insulin dynamics,
- training stimulus,
- total deficit consistency over time.
What to ask a clinic before you consider AOD-9604
If you take one thing from this article, make it this checklist.
- What is the regulatory pathway you’re using? (503A vs 503B, and what that means in practice)
- What is the source and testing standard? (COA, purity, endotoxin testing, identity confirmation)
- What route is being used and why? Safety concerns can differ by route (U.S. Food and Drug Administration)
- What is the actual goal metric? (fat mass on DEXA/in-body, waist, metabolic labs—not just scale weight)
- What is Plan A if it doesn’t move the needle? (Most responsible clinics have an off-ramp, not endless cycling)
- How do you protect lean mass? (protein target + resistance training plan)
- How are side effects monitored? (and what would stop therapy)
A reputable clinician won’t oversell AOD-9604. They’ll frame it as a possible adjunct with uncertainty—because that’s the truth.
FAQ (quick answers for common searches)
Is AOD-9604 FDA-approved for weight loss?
No. It was investigated but did not become an approved obesity drug. (PMC)
Does AOD-9604 raise IGF-1 like HGH?
Clinical safety reviews report no meaningful IGF-1 increase in monitored studies. (jofem.org)
Is AOD-9604 better than semaglutide or tirzepatide?
For clinically meaningful weight loss, GLP-1/GIP therapies have far stronger outcomes in major trials. (PubMed)
Can you take AOD-9604 with semaglutide/tirzepatide?
Some clinics discuss stacking, but robust human outcomes data for the combination are limited. If a clinic promises “guaranteed synergy,” be skeptical.
Why was AOD-9604 discontinued as a drug?
It showed modest results and later studies did not support a strong enough obesity-drug profile for commercial viability. (PMC)
Is AOD-9604 banned in sports?
WADA’s prohibited list references growth hormone fragments including AOD-9604/hGH 176–191. (wada-ama.org)
The clinical bottom line (Meto-style)
AOD-9604 is a legitimate fat-metabolism peptide in the sense that it has:
- a plausible mechanism,
- preclinical support,
- and a history of controlled human trials. (jofem.org)
But it is not in the same efficacy universe as GLP-1/GIP medications for weight loss, and it should not be positioned that way. (PubMed)
If AOD-9604 re-enters mainstream clinical availability through compliant channels, the most responsible use-case will likely be:
- carefully selected patients,
- realistic expectations,
- body composition focus,
- and as an adjunct—not a centerpiece.
Where Meto fits in this conversation
At Meto, the goal isn’t to chase trends—it’s to match tools to physiology.
If you’re exploring peptides because:
- GLP-1 side effects are limiting,
- you’ve plateaued and want a smarter plan,
- or you’re trying to lose fat without sacrificing muscle,
then the right next step is a structured metabolic review: what’s driving weight, what’s driving hunger, what’s driving adherence, and which interventions actually address your bottleneck.
Recommended For You
FDA Peptide Decision 2026: The Final Vote on BPC-157, TB-500, MOTS-c and More — What It Means for You
Across July 23–24, 2026, the FDA's advisory committee recommended six peptides for legal compounding — BPC-157, KPV, TB-500, MOTS-c, epitalon, and Semax — and rejected one, emideltide (DSIP). Here's the complete scorecard, what it means, what it doesn't, and what to do next.
FDA Advisory Committee Votes to Ease Peptide Restrictions: What the July 2026 Vote on BPC-157, KPV, TB-500, and MOTS-c Actually Means
An FDA advisory committee voted on July 23, 2026 to recommend easing restrictions on four peptides — BPC-157, KPV, TB-500, and MOTS-c. Here's what that vote actually does, why it isn't an approval, and what it means for your health.
GLP-1 and Fertility: Emerging Evidence for Women With Obesity, Insulin Resistance, and PMOS
GLP-1 fertility research in women with PMOS and insulin resistance shows consistent improvements in ovulation, menstrual regularity, and androgen levels. This deep dive covers the clinical evidence, mechanisms, who benefits most, and how to approach a PMOS fertility metabolic plan.